Objective To describe the evolution of soluble fms-like tyrosine kinase-1 to placental growth factor 
INTRODUCTION
Early-onset fetal growth restriction (FGR) is at the most severe end of the spectrum of placental dysfunction-related disorders. The diagnosis of early-onset FGR of placental origin is made when a fetus is identified as having an estimated fetal weight < 10 th centile along with abnormal Doppler findings before 32 weeks of gestation, provided that the most common genetic and infectious etiologies have been excluded 1 . Placental dysfunction tends to evolve as fetal nutritional requirements increase, although distinct progression of fetal severity and outcomes may occur. Delaying delivery until severe abnormalities are observed on fetal Doppler or cardiotocography is encouraged in an attempt to improve infant outcome 2 , but this exposes the mother and the fetus to the risk of developing additional placental dysfunction-related complications, including pre-eclampsia (PE), placental abruption and intrauterine demise.
Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are angiogenic-related biomarkers of placental dysfunction which can be used in automated assay platforms and are accepted for clinical use in Europe 3 . High sFlt-1/PlGF ratio 4 and low PlGF values 5 have been demonstrated to precede by several weeks the development of clinical PE. Abnormal angiogenic state has also been described in FGR, placental abruption and intrauterine demise 6 . Preliminary reports support the hypothesis that serial measurements of sFlt-1/PlGF ratio may be useful for monitoring patients already diagnosed with placental dysfunction-related disease, as the absolute value of the ratio correlates inversely with the remaining time to delivery and the risk for imminent obstetric complications 7, 8 . The main objective of this study was to describe the evolution of sFlt-1, PlGF and sFlt-1/PlGF ratio values in singleton pregnancies complicated by early-onset FGR in the last 5 weeks prior to delivery, and to assess if these differ between cases that additionally develop PE and those that do not.
METHODS
This was an observational prospective cohort study conducted at a single tertiary care referral center. We included all consecutive cases of early-onset FGR (diagnosed before 32 + 0 weeks of gestation) 1 that were managed at our hospital between February 2014 and July 2016, regardless of their PE status. All patients provided written informed consent to participate in the study. Exclusion criteria were multiple pregnancy, fetuses with chromosomal anomalies, major malformations or congenital infection, unknown pregnancy outcome and lack of informed consent. The study was approved by the local ethics committee.
The study population was enrolled following two different pathways. Firstly, we included pregnant women considered to have an increased risk for placental dysfunction-related disorders and who were later diagnosed with early-onset FGR in our center. These women were selected based on their personal history and uterine artery resistance measurements at the time of the routine 20-week anomaly scan. We proposed intensive monitoring to women with a history of high risk for PE, according to the National Institute for Health and Care Excellence guidelines 9 , and mean uterine artery pulsatility index (UtA-PI) ≥ 75 th centile, as well as to women presenting only with mean UtA-PI ≥ 95 th centile. In the latter group, it was additionally required that the uterine artery resistances remained above the 95 th centile at 24-28 weeks 6 . Secondly, we included patients with already established early-onset placental dysfunction-related disorders (PE or FGR).
Intensive monitoring consisted of serial visits that included a fetal growth scan and measurement of blood pressure, protein/creatinine ratio and sFlt-1/PlGF ratio. The sFlt-1 and PlGF concentrations (pg/mL) in maternal serum samples were obtained using an automated assay system (Cobas ® 6000 e701 module, Roche Diagnostics, Penzberg, Germany). The sFlt-1/PlGF ratio was calculated and expressed in absolute values. Previously described cut-off values of 38 (high suspicion of PE) 10 , 85 (aids diagnosis of PE) 3 and 655 (high risk for imminent delivery) 7 were used for the interpretation of results.
In women considered to be at high risk for placental dysfunction-related disorders, the first measurement of sFlt-1/PlGF ratio was performed at around 26 (range, 24-28) weeks. In the absence of clinical disease, follow-up measurements were scheduled based on the last sFlt-1/PlGF ratio result: if the ratio was under the cut-off point of 38, no additional measurement was made unless a suspicion of PE or FGR arose further; if the ratio was between 38 and 85 the next measurement was planned within 2 weeks and if the ratio was above 85, it was scheduled every 48-96 h. Once FGR or PE was diagnosed, the sFlt-1/PlGF ratio was also re-evaluated every 48-96 h. Physicians were aware of the results, but these were only used to guide the frequency of visits. Indication for delivery was guided by current protocols, as described below, and was not influenced by the biomarkers.
FGR was defined as ultrasound-estimated fetal weight 11 < 3 rd centile, or estimated fetal weight < 10 th centile plus abnormal fetal Doppler (umbilical artery pulsatility index > 95 th centile, middle cerebral artery pulsatility index < 5 th centile or cerebroplacental ratio < 5 th centile) 12 . Birth weight was converted into a centile after correction for gestational age, fetal gender and customization by maternal characteristics, using the GROW software 13 . Gestational age was calculated according to the recommendations of The American College of Obstetricians and Gynecologists, according to which, accurate recall of the last menstrual period was respected unless there was a significant discrepancy with the first ultrasound estimation based on measurement of the crown-rump length before 14 + 0 weeks or biparietal diameter from 14 + 0 weeks onwards 14 . Fetal surveillance was based on a previously defined stage-based protocol to monitor fetal wellbeing and to decide the timing and route of delivery in FGR 15 . Postnatal follow-up for at least 6 months was available for all survivors.
PE was defined according to the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy 16 . Maternal indications for expeditious delivery at 33 + 6 weeks or earlier were the presence of clinical conditions that contraindicate expectant management 17 . Immediate delivery was also indicated in severe PE at 34 + 0 weeks or later, whereas in non-severe forms of PE expectant management was recommended until 37 + 0 weeks.
After a diagnosis of FGR or PE was made, a cycle of corticoids for fetal maturity (betamethasone 12 mg/day for 2 days) was administered at or beyond 24 + 0 weeks and after parental counseling. A second cycle of corticoids and magnesium sulfate for fetal neuroprotection was administered in those cases at risk for imminent delivery at or before 31 + 6 weeks.
Demographic variables were expressed as mean ± SD or percentage (%). Univariable comparisons between cases with and those without PE were performed using the Student's t-test or Mann-Whitney U-test for continuous variables and the chi-square or Fisher's exact test for categorical variables. Basic statistics for the non-normally distributed values of sFlt-1 (pg/mL), PlGF (pg/mL) and the sFlt-1/PlGF ratio were described (median, interquartile range) and comparisons for these markers were performed with non-parametric tests. For longitudinal analysis of the change in sFlt-1, PlGF and sFlt-1/PlGF ratio values, we analyzed the following time intervals according to the remaining time to delivery: > 35 days, 29-35 days, 22-28 days, 15-21 days, 8-14 days, 3-7 days and ≤ 2 days to delivery. A maximum of one measurement per interval was included from each subject. When more than one measurement was available for the same interval, the one closest to delivery was chosen. Absolute values of the markers for each time interval, as well as increases from the previous interval (in percentage per day) were calculated when available. The P-value was two-sided for all tests and P < 0.05 was considered statistically significant. Data were carefully entered (by I.H. and M.S.Q.) and analyzed after data cleansing, using statistical package IBM SPSS Statistics 20.
RESULTS
We studied 74 singleton pregnancies with early-onset FGR. Most women (n = 43, 58%) were referred from other centers and the remaining were primarily attending our hospital. Inclusion, definitive diagnosis and outcomes of the study population are summarized in Figure 1 . All referred patients had a diagnosis of early-onset placental dysfunction-related disorder at inclusion, mostly FGR (n = 33, 77%), whilst the remaining 10 cases were originally diagnosed with PE and subsequently developed FGR. On the contrary, only four (13%) cases from our center were included with an established diagnosis of early-onset disease, and most (n = 27, 87%) were identified through our protocol for selection and intensive monitoring of women at high risk for placental dysfunction-related disorders. Of these, 19/27 (70%) initially presented with FGR and 8/19 (42%) of them subsequently developed PE. One case was lost to follow-up, thus the final outcome was known for 73/74 (99%) cases. Of the total cohort with known outcome, 36/73 (49%) cases were additionally complicated by PE and in 14/36 (39%) of these the diagnosis of PE was made after the diagnosis of FGR. The overall perinatal survival was 63/73 (86%). Four additional deaths occurred beyond the perinatal period and within the first 3 months postpartum; two had an extremely low birth weight, one had a sudden death and the remaining died due to sepsis. Therefore, the overall survival rate was 81%.
Maternal and pregnancy characteristics of the study group, according to presence or absence of PE, are shown in Table 1 . Women of Hispanic ethnicity and non-smokers were more prone to developing PE. Maternal and perinatal outcomes, according to presence or absence of PE, are shown in Table 2 . Time from diagnosis of FGR to delivery was significantly shorter by 1.6 (95% CI, 0.5-2.6) weeks in cases with concurrent PE. For the entire group of liveborns, gestational age at delivery was 29.9 ± 2.8 weeks and birth weight was 958 ± 365 g, with no significant differences between cases with and those without PE. However, in the neonatal death group, both gestational age at delivery and birth weight were significantly lower (25.6 ± 1.6 weeks and 538 ± 145 g, respectively) in comparison to survivors (P < 0.01).
Distribution of levels of sFlt-1, PlGF and sFlt-1/PlGF ratio at different time intervals until delivery in pregnancies affected by early-onset FGR alone compared to those with concurrent PE are presented in Figure 2 . In addition, distribution of the percentage increase of these markers between the time intervals are presented Perinatal survival (n = 63):
• FGR without PE (n = 32)
• FGR with PE (n = 31)
Neonatal death (n = 6):
• FGR without PE (n = 1)
• FGR with PE (n = 5) Figure 1 Flowchart showing inclusion, diagnosis and outcome of pregnancies with early-onset fetal growth restriction (FGR). IUD, intrauterine demise; PE, pre-eclampsia; TOP, termination of pregnancy.
in Figure 3 . Table 3 also details the measures of central tendency and dispersion of these biomarkers throughout the studied time intervals, their increment from the previous period, the proportion of cases with sFlt-1/PlGF ratio above the established cut-offs of 38, 85 and 655 and the proportion of women with typical features of PE (hypertension and proteinuria) in both groups. From 4 weeks before delivery, blood pressure, proteinuria and sFlt-1/PlGF ratio were significantly higher in the group of Only 8% of isolated FGR cases had a sFlt-1/PlGF ratio above 655 in the last 48 h before delivery and none had values beyond this threshold in the last week of pregnancy. However, most cases (65%) of FGR with PE had values above 655 in the last 48 h and 39% in the last week before delivery. 
DISCUSSION
The findings of this study show that, in early-onset FGR, the sFlt-1/PlGF ratio is abnormally elevated from 4 weeks before delivery and it is usually above the thresholds proposed for the suspicion and diagnosis of PE, 19 (100) 24 (88.9)
28 (100) 23 ( regardless of the presence of maternal disease. Moreover, the absolute value of the ratio increases progressively as the time of delivery approaches, which is especially marked if PE is also present. This change in the ratio is mainly due to the increase in sFlt-1, which is the parameter that better reflects the progression of maternal disease.
The perinatal survival in our study was 86%, which is close to that of 92% reported recently by other similar European centers 18 . However, this previous study excluded referred patients, who are more likely to have a greater severity of disease, which may explain the slightly higher weight and gestational age at birth in their cohort compared with ours (1013 vs 958 g and 30 + 5 vs 29 + 6 weeks, respectively). Other obstetric and neonatal outcomes, such as the high frequency of prenatal corticoid administration (92% vs 97%) and elective Cesarean indication (97% vs 96%), are similar between the study of Lees et al. 18 and ours, indicating that the current population and perinatal management are quite similar to those of other centers. The proportion of cases additionally complicated by PE was also very similar between our study and theirs (52% vs 50%), reflecting the importance of considering this entity when managing early-onset FGR. In fact, once FGR is diagnosed, we observed that the association of PE not only threatens maternal health but also anticipates the need to deliver in a mean of 1.6 weeks.
The usefulness of automated determination of the sFlt-1/PlGF ratio when PE is suspected has been demonstrated in the clinical setting 10 , as it can help confirm the diagnosis 19 and estimate the remaining time to delivery 20 , especially in early-onset forms. However, in other placental dysfunction-related disorders, and FGR in particular, the sFlt-1/PlGF ratio can exceed the cut-offs for PE 21 . We observed that almost all pregnancies complicated by early-onset FGR without PE exceeded the cut-off value of 38, proposed for the suspicion of PE, and 75% exceeded the cut-off value of 85, proposed for the diagnosis of PE. Therefore, these cut-offs are not necessarily pathognomonic for PE but for placental dysfunction-related disorders in general. However, although it has been stated previously that the profile of angiogenic imbalance is similar in PE and FGR 22 , our findings show that PE contributes to a further increase of the already elevated value of the sFlt-1/PlGF ratio associated with early-onset FGR, especially by means of highly elevated sFlt-1. This leads to higher values of the ratio in the FGR with PE group, that become significant from 4 weeks before delivery, although the diagnosis of PE may not be made in many cases until the last 2 weeks of gestation. The increase in sFlt-1/PlGF ratio becomes more accentuated closer to delivery, and in fact, exceeding the threshold of 655 makes very likely an imminent delivery in the context of worsening PE, with this threshold being found rarely in isolated FGR. This might be useful in the clinical setting, for example, to adjust the timing of administration of corticoids and magnesium sulfate.
However, in cases of isolated early-onset FGR, the sFlt-1/PlGF ratio remains more stable over time and serial determinations are unlikely to have an added value for clinical decision-making.
A previous study of a small sample of pre-eclamptic women in which serial measurements of the sFlt-1/PlGF ratio were performed until delivery, found an increase of 23% per day in early-onset cases, with a mean time to delivery of 6 days 23 . This is in agreement with our results of 24% increase per day in the FGR + PE group in the last week before delivery. We observed that, in most cases of early-onset placental dysfunction, sFlt-1/PlGF ratio values were elevated from at least 1 month before delivery, as predicted by other studies 6, 23 . However, our findings show that the rate of increase is slow unless we are facing the final stage of progression of PE. Another study of 100 patients with early-and late-onset PE found a 14% increase per day in cases with adverse outcomes, and a 7% increase in cases without adverse outcomes, but again without significant differences 24 . However, as in this previous study and in ours, clear differences between more and less favorable cases are observed when analyzing absolute values of the sFlt-1/PlGF ratio.
We acknowledge some limitations of our study. Firstly, the number of cases is small but, as far as we know, this study is the largest performed so far on the evolution of the sFlt-1/PlGF ratio in early-onset FGR. Moreover, the sFlt-1/PlGF ratio could be obtained before the onset of FGR or FGR + PE in a substantial proportion of cases (36%), which allowed us to assess the evolution of these markers from an earlier stage. Furthermore, our study includes serial measurements of the sFlt-1/PlGF ratio at shorter intervals, thereby providing more accurate information on its longitudinal changes. Secondly, given the insufficient sample size, no adjustments have been attempted for other parameters that could influence angiogenic marker values, such as gestational age, fetal weight and maternal characteristics. Because of this, the significant differences in ethnicity and smoking status between the two groups could have influenced the comparisons of the results of the sFlt-1/PlGF ratio, since sFlt-1 has been found to be lower in Caucasians and smokers and PlGF is lower in Caucasians and non-smokers 25, 26 . Finally, we did not differentiate between cases with and those without adverse maternal outcomes, assuming PE to be a surrogate marker of increased risk of complications. Therefore, further studies are needed to confirm whether the use of sFlt-1/PlGF ratio can help improve maternal and perinatal prognosis by introducing adequate actions based on the results of the markers.
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